Epidural-Related Fever and Maternal and Neonatal Morbidity: A Systematic Review and Meta-Analysis.


Journal

Neonatology
ISSN: 1661-7819
Titre abrégé: Neonatology
Pays: Switzerland
ID NLM: 101286577

Informations de publication

Date de publication:
2020
Historique:
received: 19 09 2019
accepted: 15 11 2019
pubmed: 29 1 2020
medline: 1 9 2021
entrez: 29 1 2020
Statut: ppublish

Résumé

While epidural analgesia (EA) is associated with maternal fever during labor, the impact on the risk for maternal and/or neonatal sepsis is unknown. The aim of this systematic review was to investigate the effect of epidural-related intrapartum fever on maternal and neonatal outcomes. OVID MEDLINE, OVID Embase, the Cochrane Library, Cochrane Controlled Register of Trials, and clinical trial registries were searched for randomized controlled trials (RCT) and observational cohort studies from inception to November 2018. A total of 761 studies were identified with 100 eligible for full-text review. Only articles investigating the relationship between EA and maternal fever during labor were eligible for inclusion. Study quality was assessed using the Cochrane's Risk of Bias tool and National Institute of Health Quality Assessment Tool. Two meta-analyses - one each for the RCT and observational cohort groups - were performed using the random-effects model of Mantel-Haenszel to produce summary risk ratios (RR) with 95% CI. Twelve RCTs and 16 observational cohort studies involving 579,157 parturients were included. RRs for maternal fever for the RCT and cohort analyses were 3.54 (95% CI 2.61-4.81) and 5.60 (95% CI 4.50-6.97), respectively. Meta-analyses of RR for maternal infection in both groups were infeasible given few occurrences. Meta-analysis of data from observational studies showed an increased risk for maternal antibiotic treatment in the epidural group (RR 2.60; 95% CI 1.31-5.17). For both analyses, neonates born to women with an epidural were not evaluated more often for suspected sepsis. Neither analysis reported an increased rate of neonatal bacteremia or neonatal antibiotic treatment after EA, although data precluded conclusiveness. EA increases the risk of intrapartum fever and maternal antibiotic treatment. However, a definite conclusion on whether EA increases the risk for a proven maternal and/or neonatal bacteremia cannot be drawn due to the low quality of data. Further research on whether epidural-related intrapartum fever is of infectious origin or not is therefore needed.

Sections du résumé

BACKGROUND
While epidural analgesia (EA) is associated with maternal fever during labor, the impact on the risk for maternal and/or neonatal sepsis is unknown.
OBJECTIVES
The aim of this systematic review was to investigate the effect of epidural-related intrapartum fever on maternal and neonatal outcomes.
METHODS
OVID MEDLINE, OVID Embase, the Cochrane Library, Cochrane Controlled Register of Trials, and clinical trial registries were searched for randomized controlled trials (RCT) and observational cohort studies from inception to November 2018. A total of 761 studies were identified with 100 eligible for full-text review. Only articles investigating the relationship between EA and maternal fever during labor were eligible for inclusion. Study quality was assessed using the Cochrane's Risk of Bias tool and National Institute of Health Quality Assessment Tool. Two meta-analyses - one each for the RCT and observational cohort groups - were performed using the random-effects model of Mantel-Haenszel to produce summary risk ratios (RR) with 95% CI.
RESULTS
Twelve RCTs and 16 observational cohort studies involving 579,157 parturients were included. RRs for maternal fever for the RCT and cohort analyses were 3.54 (95% CI 2.61-4.81) and 5.60 (95% CI 4.50-6.97), respectively. Meta-analyses of RR for maternal infection in both groups were infeasible given few occurrences. Meta-analysis of data from observational studies showed an increased risk for maternal antibiotic treatment in the epidural group (RR 2.60; 95% CI 1.31-5.17). For both analyses, neonates born to women with an epidural were not evaluated more often for suspected sepsis. Neither analysis reported an increased rate of neonatal bacteremia or neonatal antibiotic treatment after EA, although data precluded conclusiveness.
CONCLUSION
EA increases the risk of intrapartum fever and maternal antibiotic treatment. However, a definite conclusion on whether EA increases the risk for a proven maternal and/or neonatal bacteremia cannot be drawn due to the low quality of data. Further research on whether epidural-related intrapartum fever is of infectious origin or not is therefore needed.

Identifiants

pubmed: 31991422
pii: 000504805
doi: 10.1159/000504805
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

259-270

Informations de copyright

© 2020 The Author(s) Published by S. Karger AG, Basel.

Auteurs

Sophie Jansen (S)

Department of Neonatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands, s.j.jansen@lumc.nl.

Enrico Lopriore (E)

Department of Neonatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.

Christiana Naaktgeboren (C)

University Medical Center Utrecht (UMCU), Department of Data Management and Research Support, Julius Center for Health Science and Primary Care, Utrecht, The Netherlands.

Marieke Sueters (M)

Department of Obstetrics and Gynecology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.

Jacqueline Limpens (J)

Medical Library, Research Support, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, The Netherlands.

Elisabeth van Leeuwen (E)

Department of Obstetrics and Gynecology, Amsterdam University Medical Center (UMC), Amsterdam, The Netherlands.

Vincent Bekker (V)

Department of Neonatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
Center for Infection and Immunity Amsterdam (CINIMA), Emma Children's Hospital, Amsterdam University Medical Center (UMC), Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH